OvaSciencePublicly available records indicate that a class action lawsuit has been filed on behalf of investors in OvaScience (NASDAQ:OVAS) in connection to alleged violations of securities laws by OVAS. Fitapelli Kurta is interested in speaking to investors who have complaints regarding investments made in OvaScience between January 8, 2015 and November 22, 2017.

The class action complaint specifically alleges that during the period in question, OVAS might have provided false and/or misleading material information, and/or failed to disclose adverse material information to the public, chiefly: in the filings on January 8, 2015 OvaScience made materially false statements and omissions of fact, for instance, that roughly 150 patients in OVAS’s 2014 AUGMENT treatment had not experienced a pregnancy success rate notably above the rate observed in patients who had not undergone the treatment; that there were uncertainties regarding the science underlying the AUGMENT treatment; and that the company did not choose, but had been forced to perform its studies in countries other than the United States, due to costly federal regulations it did not wish to satisfy; and that OVAS was far from achieving profitability.. The complaint alleges that when true facts came to light, investors suffered losses.

According to the company’s website, OvaScience is a biotechnology company focused on female fertility and “dedicated to improving treatment options for women around the world.” The AUGMENT treatment is a procedure designed to improve egg health, offered in certain IVF clinics outside of the United States. The company is also developing OvaPrime, a treatment that could increase a woman’s egg reserve, and OvaTure, an IVF treatment that could help women produce healthy and fertilizable eggs without hormone injections.

A class action lawsuit has already been filed in connection with OvaScience. If you wish to serve as lead plaintiff in the OVAS lawsuit, you must move the Court no later than January 22, 2018. If you wish to join the litigation, please contact Marc Fitapelli at 212-658-1501 or Jonathan Kurta at 212-658-1502. There is no cost or obligation to you and your ability to share in any recovery does not require that you serve as a lead plaintiff.